Glioma marker group and application thereof

Abstract

The invention belongs to the field of biological and medical examination, and relates to a group of tumor markers for glioma identification, molecular typing, malignant grading and prognosis evaluation and application thereof. The related genes comprise ISL2, OSR2, TNFRSF11B, CABP4, CCDC18, IQGAP2, EFNB1, OTP, COL4A2, HIST1H3H, SERPINA5, PLSCR1, IGF2BP2, CEP135, HOXD10, LAMA2, ARAP3, GLA, FNDC3B, PYGL, PIGY, BCAN, CD68, CPXM1, SOX4, MDFI, CCDC80, TIMP4, TREM2, TCF12, MASP1, SRPX, UBE2C, MS4A6A, C1QC, PDPN, ANXA2, WEE1, HIST1H2BJ, ANG, EN1, ZNF217 The expression quantity difference of products (protein and RNA) of the gene (single gene or any combination) can be used for predicting the existence of glioma, molecular typing, targeted drug screening, malignant grade and the total lifetime of a patient. When the optimal combination of the markers is used for identifying normal brain tissues and glioma, the sensitivity can reach 97% or above when the specificity is greater than 99%. The marker can be directly applied and can also be combined with WHO pathological grading, 1p19q mutation state and the like.

Description

technical field [0001] The invention belongs to the field of biological and medical testing, and relates to a group of tumor markers and applications for glioma identification, molecular typing, malignant grading and prognosis evaluation; the involved genes include: ISL2, OSR2, TNFRSF11B, CABP4, CCDC18, IQGAP2, EFNB1, OTP, COL4A2, HIST1H3H, SERPINA5, PLSCR1, IGF2BP2, CEP135, HOXD10, LAMA2, ARAP3, GLA, FNDC3B, PYGL, PIGY, BCAN, CD68, CPXM1, SOX4, MDFI, CCDC80, TIMP4, TREM2, 44 genes including TCF12, MASP1, SRPX, UBE2C, MS4A6A, C1QC, PDPN, ANXA2, WEE1, HIST1H2BJ, ANG, EN1, ZNF217, EMILIN3, TMEM100, etc. The marker includes the gene product (protein, RNA), and predicts the existence of glioma by using the close relationship between the change of the gene expression and the carcinogenesis of glial tissue, the grade of malignancy and the prognosis of the patient. Molecular typing, targeted drug screening, malignancy grade and overall survival of patients. Background technique ...

AI Technical Summary

Problems solved by technology

[0005] Although the gene is closely related to the occurrence and development of tumors or gliomas, it is not fully used in the identification, molecular typing, malignant grading and prognosis assessment of gliomas

Among them, ISL2, OSR2, TNFRSF11B, CABP4, CCDC18, IQGAP2, EFNB1, OTP, COL4A2, HIST1H3H, SERPINA5, PLSCR1, IGF2BP2, CEP135, HOXD10, LAMA2, ARAP3, GLA, FNDC3B, PYGL, PIGY, BCAN, CD68, CPXM1, SOX4 , MDFI, CCDC80, TIMP4, TREM2, TCF12, MASP1, SRPX and other genes in the identification, molecular typing, malignant grading and prognosis evaluation of glioma have not been reported in the literature

However, the combination of two or more genes of said genes has not been reported for the identification, molecular typing, malignant grading and prognosis evaluation of gliomas.

Images